Skip to main content
. 2018 Nov 25;85(2):347–355. doi: 10.1111/bcp.13794

Figure 3.

Figure 3

Mean changes in BCVA (ETDRS letters) (A) and CRT (B) in patients with neovascular age‐related macular degeneration (n = 20) who received rescue medication (intravitreal ranibizumab) after prior regorafenib treatment. BCVA, best‐corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; SE, standard error